Skip to main content

Epigenetic Biomarkers

Edited by Dawn DeMeo, James Flanagan, Harold Snieder, and Tomasz K. Wojdacz

New Content ItemClinical Epigenetics invites you to contribute a manuscript to our new thematic series, “Epigenetic Biomarkers”.

Epigenetic biomarkers have significantly contributed to improved understanding of the origins and progression of disease.  Moreover, increasing evidence shows that epigenetic biomarkers have potential for personalized medicine. However, routine use of epigenetic biomarkers in in-vitro diagnostics (IVD) is lagging behind the discoveries of new biomarkers. In this thematic series of Clinical Epigenetics, we discuss current progress in development of epigenetic biomarkers for clinical use in common complex diseases of ageing and welcome both original research and reviews.

The sections of the collection include:

  1. Types of epigenetic biomarkers and readiness for IVD use
    1. DNA methylation as biomarker
    2. Histone modification as biomarker
    3. Upcoming field of circulating free nucleosomes as biomarker
  2. Progress towards clinical use of biomarker

    1. Biomarkers of environmental exposures and causality of the biomarker

    2. Disease predisposition biomarkers

    3. Biomarkers used for disease detection

    4. Clinical disease prevention and management: predictive and prognostic

    5. Monitoring of chronic disease

  3. Single versus multiple biomarkers and risk scores
  4. Major stages of clinical validation of the biomarker
  5. Biomarker detection technologies suitable for IVD use and significance of bioinformatics
  6. Ethics and regulatory aspects of IVD epigenetic biomarkers

This collection of articles has not been sponsored and articles have undergone the journal’s standard peer-review process. Please find out more about our journal and its policies, here. Submission guidelines can be found here, and please submit to the series via our submission system (there will be a field for which you can indicate if you are submitting to this series).

All submissions should be made by December 1st, 2021.

  1. DNA methylation biomarkers for early detection, risk stratification and treatment response in cancer have been of great interest over the past decades. Nevertheless, clinical implementation of these biomarkers...

    Authors: Maartje Massen, Kim Lommen, Kim A. D. Wouters, Johan Vandersmissen, Wim van Criekinge, James G. Herman, Veerle Melotte, Leo J. Schouten, Manon van Engeland and Kim M. Smits
    Citation: Clinical Epigenetics 2022 14:56
  2. Multiple studies have reported the prognostic impact of DNA methylation changes in acute myeloid leukemia (AML). However, these epigenetic markers have not been thoroughly validated and therefore are still not...

    Authors: Šárka Šestáková, Ela Cerovská, Cyril Šálek, Dávid Kundrát, Ivana Ježíšková, Adam Folta, Jiří Mayer, Zdeněk Ráčil, Petr Cetkovský and Hana Remešová
    Citation: Clinical Epigenetics 2022 14:22
  3. Although kidney transplantation improves patient survival and quality of life, long-term results are hampered by both immune- and non-immune-mediated complications. Current biomarkers of post-transplant compli...

    Authors: Iacopo Cristoferi, Tommaso Antonio Giacon, Karin Boer, Myrthe van Baardwijk, Flavia Neri, Manuela Campisi, Hendrikus J. A. N. Kimenai, Marian C. Clahsen - van Groningen, Sofia Pavanello, Lucrezia Furian and Robert C. Minnee
    Citation: Clinical Epigenetics 2022 14:20
  4. Epigenetic clocks are biomarkers of ageing derived from DNA methylation levels at a subset of CpG sites. The difference between age predicted by these clocks and chronological age, termed “epigenetic age accel...

    Authors: Rhona A. Beynon, Suzanne M. Ingle, Ryan Langdon, Margaret May, Andy Ness, Richard M. Martin, Matthew Suderman, Kate Ingarfield, Riccardo E. Marioni, Daniel L. McCartney, Tim Waterboer, Michael Pawlita, Caroline Relton, George Davey Smith and Rebecca C. Richmond
    Citation: Clinical Epigenetics 2022 14:1
  5. Circulating tumor DNA (ctDNA) is a promising diagnostic and prognostic marker for many cancers and has been actively investigated in recent years. Previous studies have already demonstrated the potential use o...

    Authors: Wu-Hao Lin, Jian Xiao, Zi-Yi Ye, Da-Liang Wei, Xiao-Hui Zhai, Rui-Hua Xu, Zhao-Lei Zeng and Hui-Yan Luo
    Citation: Clinical Epigenetics 2021 13:232
  6. Metformin and weight loss relationships with epigenetic age measures—biological aging biomarkers—remain understudied. We performed a post-hoc analysis of a randomized controlled trial among overweight/obese br...

    Authors: Jamaji C. Nwanaji-Enwerem, Felicia Fei-Lei Chung, Lars Van der Laan, Alexei Novoloaca, Cyrille Cuenin, Harriet Johansson, Bernardo Bonanni, Alan E. Hubbard, Martyn T. Smith, Sheri J. Hartman, Andres Cardenas, Dorothy D. Sears and Zdenko Herceg
    Citation: Clinical Epigenetics 2021 13:224
  7. Early lung cancer detection remains a clinical challenge for standard diagnostic biopsies due to insufficient tumor morphological evidence. As epigenetic alterations precede morphological changes, expression a...

    Authors: Jian Zhou, Tong Cheng, Xing Li, Jie Hu, Encheng Li, Ming Ding, Rulong Shen, John P. Pineda, Chun Li, Shaohua Lu, Hongyu Yu, Jiayuan Sun, Wenbin Huang, Xiaonan Wang, Han Si, Panying Shi…
    Citation: Clinical Epigenetics 2021 13:220
  8. The dilation of the aorta that occurs as a consequence of a congenitally bicuspid aortic valve (BAV) is associated with a risk of dissection, aneurysm or rupture. With progressive aortopathy, surgery is often ...

    Authors: Ashna Maredia, David Guzzardi, Mohammad Aleinati, Fatima Iqbal, Arshroop Khaira, Aiswarya Madhu, Xuemei Wang, Alex J. Barker, Patrick M. McCarthy, Paul W. M. Fedak and Steven C. Greenway
    Citation: Clinical Epigenetics 2021 13:147
  9. Increasing evidence linking epigenetic mechanisms and different diseases, including cancer, has prompted in the last 15 years the investigation of histone post-translational modifications (PTMs) in clinical sa...

    Authors: Roberta Noberini, Evelyn Oliva Savoia, Stefania Brandini, Francesco Greco, Francesca Marra, Giovanni Bertalot, Giancarlo Pruneri, Liam A. McDonnell and Tiziana Bonaldi
    Citation: Clinical Epigenetics 2021 13:145
  10. Current risk models for renal cell carcinoma (RCC) based on clinicopathological factors are sub-optimal in accurately identifying high-risk patients. Here, we perform a head-to-head comparison of previously pu...

    Authors: S. C. Joosten, S. N. O. Odeh, A. Koch, N. Buekers, M. J. B. Aarts, M. M. L. L. Baldewijns, L. Van Neste, S. van Kuijk, L. J. Schouten, P. A. van den Brandt, V. C. Tjan-Heijnen, M. van Engeland and K. M. Smits
    Citation: Clinical Epigenetics 2021 13:103